Binod Dhakal, MD, discusses responses achieved with orvacabtagene autoleucel in patients with multiple myeloma.
Binod Dhakal, MD, an associate professor of medicine in the Division of Hematology at the Medical College of Wisconsin, discusses responses achieved with orvacabtagene autoleucel (orva-cel; JCARH125) in patients with multiple myeloma.
Sixty-two patients with relapsed/refractory multiple myeloma were enrolled to the phase 1/2 EVOLVE study (NCT03430011), which evaluated the CAR T-cell therapy. Participants received 3 different doses of orva-cel: 300 × 106 , 450 × 106 , and 600 × 106 CAR+ T cells after lymphodepletion with fludarabine/cyclophosphamide, Dhakal says. Notably, patients were considered to be heavily pretreated, having received a median of 6 prior lines of therapy. Ninety-two percent of patients were penta-exposed.
Results from the trial were presented during the 2020 ASCO Virtual Scientific Program and showed that orva-cel resulted in an overall response rate of 91%, says Dhakal. Moreover, patients who received the product at 600 × 106 CAR+ T cells experienced a favorable minimal residual disease negativity rate, Dhakal notes.
Although the median follow-up time for the trial is shorter than other studies that have been done, mature data are highly anticipated, Dhakal concludes.